Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 5
1977 1
1979 1
1980 1
1981 4
1982 6
1983 7
1984 3
1985 7
1986 4
1987 5
1988 10
1989 8
1990 6
1991 8
1992 13
1993 22
1994 10
1995 12
1996 13
1997 13
1998 12
1999 14
2000 6
2001 12
2002 12
2003 11
2004 15
2005 12
2006 18
2007 17
2008 23
2009 18
2010 23
2011 23
2012 15
2013 27
2014 30
2015 22
2016 18
2017 33
2018 39
2019 40
2020 45
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

603 results
Results by year
Filters applied: . Clear all
Page 1
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opio
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK, Schultz BG, Berlau DJ. Patten DK, et al. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
Currently, evidence supports the safety and tolerability of low-dose naltrexone in multiple sclerosis, fibromyalgia, and Crohn's disease. ...These studies do demonstrate that low-dose naltrexone has subjective benefits over placebo …
Currently, evidence supports the safety and tolerability of low-dose naltrexone in multiple sclerosis, fibromyalgia, an …
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS, Fishman MA. Kim PS, et al. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Curr Pain Headache Rep. 2020. PMID: 32845365 Review.
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltrexone in the treatment of chronic pain. RECENT FINDINGS: Recent pre-clinical uses and clinical studies further elucidate th …
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose
Low Dose Naltrexone in the Treatment of Fibromyalgia.
Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Metyas S, et al. Curr Rheumatol Rev. 2018;14(2):177-180. doi: 10.2174/1573397113666170321120329. Curr Rheumatol Rev. 2018. PMID: 28325149 Clinical Trial.
It is hypothesized that low dose naltrexone causes transient blockade of opioid receptors centrally resulting in a rebound of endorphin function which may attenuate pain in fibromyalgia. RESULTS: Two small prospective pilot studies have previously shown that …
It is hypothesized that low dose naltrexone causes transient blockade of opioid receptors centrally resulting in a rebo …
Low Dose Naltrexone in Dermatology.
Jaros J, Lio P. Jaros J, et al. J Drugs Dermatol. 2019 Mar 1;18(3):235-238. J Drugs Dermatol. 2019. PMID: 30909326
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn's disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charc
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflamma
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn'
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z, You Y, Griffin N, Feng J, Shan F. Li Z, et al. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Int Immunopharmacol. 2018. PMID: 29885638 Review.
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and signi
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to
Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.
Trofimovitch D, Baumrucker SJ. Trofimovitch D, et al. Am J Hosp Palliat Care. 2019 Oct;36(10):907-912. doi: 10.1177/1049909119838974. Epub 2019 Mar 27. Am J Hosp Palliat Care. 2019. PMID: 30917675 Review.
Low dose naltrexone has gained popularity as an off-label treatment of several autoimmune diseases including multiple sclerosis and inflammatory bowel disease, as well as chronic pain disorders including fibromyalgia, complex regional pain syndrome, and diabe
Low dose naltrexone has gained popularity as an off-label treatment of several autoimmune diseases including multiple s
Low-dose Naltrexone Therapy for Psoriasis.
Weinstock LB, Cottel J, Aldridge L, Egeberg A. Weinstock LB, et al. Int J Pharm Compd. 2020 Mar-Apr;24(2):94-96. Int J Pharm Compd. 2020. PMID: 32196470
Safe, inexpensive, and convenient psoriasis therapy is desirable. Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further the evidence of efficacy and safety of low-dose
Safe, inexpensive, and convenient psoriasis therapy is desirable. Two recent case reports suggested that low-dose naltrexon
The Use of Low-Dose Naltrexone for Chronic Pain.
Bostick KM, McCarter AG, Nykamp D. Bostick KM, et al. Sr Care Pharm. 2019 Jan 1;34(1):43-46. doi: 10.4140/TCP.n.2019.43. Sr Care Pharm. 2019. PMID: 30821677
The use of low-dose naltrexone for the treatment of chronic pain is novel because it is a nonopioid alternative. Oral naltrexone in a dosage range from 1 mg to 4.5 mg is referred to as low-dose naltrexone. ...
The use of low-dose naltrexone for the treatment of chronic pain is novel because it is a nonopioid alternative. Oral …
603 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page